This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodrigo, J. P. Articles by Suárez, C. Search for Related Content PubMed PubMed Citation Articles by Rodrigo, J. P. Articles by Suárez, C.

EMS1 Gene Amplification Correlates with Poor Prognosis in Squamous Cell Carcinomas of the Head and Neck¹

Departments of Otolaryngology-Head and Neck Surgery [J. P. R., L. A. G., C. S.] and Molecular Biology [S. R., P. S. L.], Hospital Central de Asturias, University of Oviedo, Instituto Universitario de Oncología, 33006 Oviedo, Spain

The relationship between CCND1 and/or EMS1 amplification and disease outcome was studied in a prospective series of 104 head and neck squamous cell carcinomas treated by surgical resection. The CCND1 and EMS1 copy number in tumor samples was estimated by differential PCR. The presence or absence of amplification was analyzed in relation to clinicopathological variables, tumor recurrence, and patient survival. CCND1 amplification occurred in 32 cases (31%) and was associated with increased lymph node stage (P = 0.005) and advanced disease stage (P = 0.003). EMS1 amplification was identified in 21 cases (20%) and was related with advanced T stages (P = 0.001), increased lymph node stage (P = 0.02), advanced disease stage (P = 0.041), poor histological differentiation (P = 0.018), recurrent disease (P = 0.0004), and reduced disease-specific survival (P < 0.0001). Coamplification of both genes occurred in 11 cases (11.5%). Multivariate analysis confirmed that in addition to regional lymph node status, EMS1 amplification is an independent predictor of death from the tumor (P = 0.0027). CCND1 amplification was not prognostic. These data indicate that EMS1 amplification, but not CCND1 amplification, predicts early recurrence and reduced survival in squamous cell carcinoma of the head and neck. The prognostic significance previously attributed to CCND1 amplification may be attributable to its frequent coamplification with EMS1.

This article has been cited by other articles:

				B. Singh and D. G. Pfister Individualized Treatment Selection in Patients With Head and Neck Cancer: Do Molecular Markers Meet the Challenge? J. Clin. Oncol., July 1, 2008; 26(19): 3114 - 3116. [Full Text] [PDF]

				X.-Y. Lu, Y. Lu, Y.-J. Zhao, K. Jaeweon, J. Kang, L. Xiao-Nan, G. Ge, R. Meyer, L. Perlaky, J. Hicks, et al. Cell Cycle Regulator Gene CDC5L, a Potential Target for 6p12-p21 Amplicon in Osteosarcoma Mol. Cancer Res., June 1, 2008; 6(6): 937 - 946. [Abstract] [Full Text] [PDF]

				J. H. Gibcus, L. Menkema, M. F. Mastik, M. A. Hermsen, G. H. de Bock, M.-L. F. van Velthuysen, R. P. Takes, K. Kok, C. A. Alvarez Marcos, B. F.A.M. van der Laan, et al. Amplicon Mapping and Expression Profiling Identify the Fas-Associated Death Domain Gene as a New Driver in the 11q13.3 Amplicon in Laryngeal/Pharyngeal Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6257 - 6266. [Abstract] [Full Text] [PDF]

				P. Timpson, A. S. Wilson, G. M. Lehrbach, R. L. Sutherland, E. A. Musgrove, and R. J. Daly Aberrant Expression of Cortactin in Head and Neck Squamous Cell Carcinoma Cells Is Associated with Enhanced Cell Proliferation and Resistance to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Cancer Res., October 1, 2007; 67(19): 9304 - 9314. [Abstract] [Full Text] [PDF]

				S. Skvortsov, I. Skvortsova, T. Stasyk, N. Schiefermeier, A. Neher, A. R. Gunkel, G. K. Bonn, L. A. Huber, P. Lukas, C. M. Pleiman, et al. Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-{kappa}B expression and proteasome activation in head and neck squamous carcinoma cell lines Mol. Cancer Ther., June 1, 2007; 6(6): 1898 - 1908. [Abstract] [Full Text] [PDF]

				E. S. Clark, A. S. Whigham, W. G. Yarbrough, and A. M. Weaver Cortactin Is an Essential Regulator of Matrix Metalloproteinase Secretion and Extracellular Matrix Degradation in Invadopodia Cancer Res., May 1, 2007; 67(9): 4227 - 4235. [Abstract] [Full Text] [PDF]

				M.-L. Luo, X.-M. Shen, Y. Zhang, F. Wei, X. Xu, Y. Cai, X. Zhang, Y.-T. Sun, Q.-M. Zhan, M. Wu, et al. Amplification and Overexpression of CTTN (EMS1) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance Cancer Res., December 15, 2006; 66(24): 11690 - 11699. [Abstract] [Full Text] [PDF]

				B. L. Rothschild, A. H. Shim, A. G. Ammer, L. C. Kelley, K. B. Irby, J. A. Head, L. Chen, M. Varella-Garcia, P. G. Sacks, B. Frederick, et al. Cortactin Overexpression Regulates Actin-Related Protein 2/3 Complex Activity, Motility, and Invasion in Carcinomas with Chromosome 11q13 Amplification Cancer Res., August 15, 2006; 66(16): 8017 - 8025. [Abstract] [Full Text] [PDF]

				Y. Kasugai, H. Tagawa, Y. Kameoka, Y. Morishima, S. Nakamura, and M. Seto Identification of CCND3 and BYSL as Candidate Targets for the 6p21 Amplification in Diffuse Large B-Cell Lymphoma Clin. Cancer Res., December 1, 2005; 11(23): 8265 - 8272. [Abstract] [Full Text] [PDF]

				P. Timpson, D. K. Lynch, D. Schramek, F. Walker, and R. J. Daly Cortactin Overexpression Inhibits Ligand-Induced Down-regulation of the Epidermal Growth Factor Receptor Cancer Res., April 15, 2005; 65(8): 3273 - 3280. [Abstract] [Full Text] [PDF]

				Y. Chen, G. Shi, W. Xia, C. Kong, S. Zhao, A. F. Gaw, E. Y. Chen, G. P. Yang, A. J. Giaccia, Q.-T. Le, et al. Identification of Hypoxia-Regulated Proteins in Head and Neck Cancer by Proteomic and Tissue Array Profiling Cancer Res., October 15, 2004; 64(20): 7302 - 7310. [Abstract] [Full Text] [PDF]

				P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, et al. Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting Clin. Cancer Res., October 1, 2004; 10(19): 6487 - 6501. [Abstract] [Full Text] [PDF]

				Q.-T. Le and A. J. Giaccia Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295. [Abstract] [Full Text] [PDF]

				D. K. Lynch, S. C. Winata, R. J. Lyons, W. E. Hughes, G. M. Lehrbach, V. Wasinger, G. Corthals, S. Cordwell, and R. J. Daly A Cortactin-CD2-associated Protein (CD2AP) Complex Provides a Novel Link between Epidermal Growth Factor Receptor Endocytosis and the Actin Cytoskeleton J. Biol. Chem., June 6, 2003; 278(24): 21805 - 21813. [Abstract] [Full Text] [PDF]

				K. Freier, S. Joos, C. Flechtenmacher, F. Devens, A. Benner, F. X. Bosch, P. Lichter, and C. Hofele Tissue Microarray Analysis Reveals Site-specific Prevalence of Oncogene Amplifications in Head and Neck Squamous Cell Carcinoma Cancer Res., March 15, 2003; 63(6): 1179 - 1182. [Abstract] [Full Text] [PDF]

				B.-Z. Yuan, X. Zhou, D. B. Zimonjic, M. E. Durkin, and N. C. Popescu Amplification and Overexpression of the EMS 1 Oncogene, a Possible Prognostic Marker, in Human Hepatocellular Carcinoma J. Mol. Diagn., February 1, 2003; 5(1): 48 - 53. [Abstract] [Full Text] [PDF]

				T. Ueno, A. Tangoku, S. Yoshino, T. Abe, H. Toshimitsu, T. Furuya, S. Kawauchi, A. Oga, M. Oka, and K. Sasaki Gain of 5p15 Detected by Comparative Genomic Hybridization as an Independent Marker of Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma Clin. Cancer Res., February 1, 2002; 8(2): 526 - 533. [Abstract] [Full Text] [PDF]

				Y. Li, M. Tondravi, J. Liu, E. Smith, C. C. Haudenschild, M. Kaczmarek, and X. Zhan Cortactin Potentiates Bone Metastasis of Breast Cancer Cells Cancer Res., September 1, 2001; 61(18): 6906 - 6911. [Abstract] [Full Text] [PDF]